US · Healthcare · Biotechnology
EPS came in at -0.62 against a street estimate of -0.56 — a miss of 10.7%.
Analysts rate Zymeworks Inc. Common Stock a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $41.50.
| Fund | Stake |
|---|---|
| EcoR1 Capital, LLC | 31.95% |
| Rubric Capital Management LP | 9.74% |
| BlackRock Inc | 5.91% |
| Perceptive Advisors LLC | 5.82% |
| Bvf Inc | 5.08% |
| Assenagon Asset Management SA | 3.48% |
| Morgan Stanley - Brokerage Accounts | 3.10% |
| BNP Paribas Investment Partners SA | 2.48% |
| Document | Date |
|---|---|
| Proxy statement · Q4 2026 EXECUTIVE PAY • CEO Kenneth Galbraith’s total compensation was $8,138,446 in 2025, compared with $4,331,290 in 2024, an increase of $3,807,156. • Th | 2026-10-26 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • Zymeworks granted Roche exclusive, worldwide rights to develop and commercialize ZW209, a trispecific T-cell engager targeting DLL | 2026-10-23 |
| Material agreement · Q3 2026 ZYMEWORKS INC. – 8-K SUMMARY HEADLINE NUMBERS • Merger closed: September 23, 2026. Zymeworks acquired Theravance Biopharma, Inc. • Cash consideratio | 2026-09-23 |
| Reg FD disclosure · Q3 2026 ZYMEWORKS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Zymeworks earned a $250 million milestone payment from partner Jazz Pharmaceuticals based on FD | 2026-08-25 |
| Quarterly report · Q2 2026 ZYMEWORKS INC. — Q2 2026 10-Q SUMMARY --- HEADLINE NUMBERS • Cash position: $179.4 million in cash and cash equivalents as of June 30, 2026, up fro | 2026-08-06 |
| Results announced · Q3 2026 ZYMEWORKS INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue: $4.6 million in Q2 2026 vs. $48.7 million in Q2 2025 (down 91%) - Six-month | 2026-08-06 |
| Material agreement · Q2 2026 ZYMEWORKS INC. - 8-K FILING SUMMARY HEADLINE NUMBERS • Acquisition price: $17.00 per share in cash plus one contingent value right (CVR) per share • | 2026-06-29 |
| Reg FD disclosure · Q2 2026 ZYMEWORKS INC. (ZYME) – 8-K SUMMARY HEADLINE NUMBERS • Share Repurchase Program: Board authorized new $125.0 million repurchase program (2026 Share | 2026-05-14 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive global license and collaboration agreement for ZW209 with Roche Zymeworks signed an exclusive worldwide license and collaboration agreement with Roche for ZW209, an experimental trispecific T-cell engager targeting DLL3 in cancers such as small-cell lung | 2026-10-23 |
| Merger with Theravance and financing transaction announced Zymeworks announced a merger with Theravance Biopharma that has closed or is closing. The deal includes financing through a note purchase agreement and establishes contingent value rights (C | 2026-09-23 |
| FDA approves Ziihera for first-line HER2+ gastroesophageal adenocarcinoma Zymeworks announced FDA approval of Ziihera (zanidatamab), a cancer drug developed by the company and commercialized by partner Jazz Pharmaceuticals, for treating HER2-positive gastroesophag | 2026-08-25 |
| Proposed merger with Theravance announced Zymeworks Inc. announced a proposed merger with Theravance Biopharma, Inc., with the merger agreement dated June 28, 2026. The announcement includes standard forward-looking statements about | 2026-06-29 |
| 2026 share repurchase program announced with anticipated regulatory milestone payments Zymeworks Inc. filed an 8-K on May 14, 2026, primarily containing forward-looking statements and standard SEC boilerplate language rather than material news. The company disclosed that it an | 2026-05-14 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zymeworks Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.